Full-Time

Associate Director

Global Project Management, Drug Development

Updated on 9/4/2026

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$175k - $192.5k/yr

+ Annual Bonus Program + Long Term Incentive Program

Princeton, NJ, USA

Hybrid

Hybrid role; requires up to 10% domestic and international travel.

Bachelor's, Master's, MBA, PharmD, PhD

Category
Project & Program Management (1)
Required Skills
Microsoft Office
Six Sigma
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A bachelor's degree in life science, engineering, or a related scientific discipline is required.
  • A minimum of eight years of project management experience in the pharmaceutical, biotechnology, or related life sciences industry, with progressive responsibility supporting drug development programs, is required.
  • At least five years of experience managing cross-functional drug development projects within a matrix organization is required.
  • Demonstrated success leading clinical-stage development programs from planning through execution, including governance support and cross-functional integration, is required.
  • Proven ability to manage integrated project plans, timelines, budgets, resource forecasts, and project risks across multiple functional disciplines is required.
  • A track record of influencing cross-functional teams and driving project execution without direct reporting authority is required.
  • Strong knowledge of project management principles, methodologies, and best practices is required.
  • Advanced proficiency in Microsoft Office Suite, including Word, Excel, PowerPoint, and Outlook, is required.
  • Working knowledge of the drug development lifecycle, including clinical, nonclinical, chemistry, manufacturing, and controls, regulatory, and commercialization activities, is required.
  • Demonstrated ability to apply project management tools and techniques to support strategic planning, decision-making, risk management, issue resolution, and governance is required.
  • Excellent verbal, written, facilitation, presentation, and interpersonal communication skills are required.
  • Strong leadership and collaboration skills are required to influence cross-functional teams and drive results in a global matrix environment without direct authority.
  • Exceptional organizational, analytical, and problem-solving skills are required to manage multiple priorities, evaluate complex information, and make sound business recommendations.
  • Proficiency in virtual collaboration technologies and meeting facilitation tools is required to lead global, cross-functional teams across multiple time zones.
Responsibilities
  • Lead cross-functional project management activities for global clinical-stage drug development programs, serving as the project integrator across functional areas.
  • Develop, maintain, and execute integrated project plans, including project scope, timelines, milestones, critical path, and deliverables.
  • Identify, assess, and manage project risks, issues, dependencies, and opportunities, and facilitate cross-functional mitigation and contingency plans.
  • Manage project budgets and resource plans by developing integrated budget and full-time-equivalent forecasts, monitoring performance, and recommending changes through governance and change control processes.
  • Coordinate project meetings, maintain core project documentation, and provide timely, transparent reporting of project status, risks, and key decisions.
  • Ensure project teams adhere to global development processes, governance requirements, and project management standards while applying appropriate methodologies, systems, and tools.
  • Influence and lead cross-functional teams in a matrix environment without direct authority to foster collaboration, accountability, and timely delivery.
  • Partner with internal stakeholders across One Kyowa Kirin and external alliance partners to support integrated program execution and business objectives.
  • Drive process improvements, standardize best practices, support organizational change initiatives, and share lessons learned across programs.
  • Provide coaching and mentorship to project team members and colleagues to strengthen project management capabilities.
  • Perform other duties and responsibilities as assigned, consistent with the scope and level of the position.
Desired Qualifications
  • An advanced degree such as a Master of Science, Ph.D., Pharm.D., Master of Business Administration, or equivalent is preferred.
  • Project Management Professional certification is highly preferred.
  • Six Sigma Green Belt certification or higher is preferred.
  • Experience collaborating with external partners, contract research organizations, and strategic alliances is preferred.
  • Participation in process improvement, organizational change initiatives, or implementation of project management best practices is preferred.
  • Experience with Planisware is preferred.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.